These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9890058)

  • 1. An introduction to analytical methods for the postmarketing surveillance of veterinary vaccines.
    Siev D
    Adv Vet Med; 1999; 41():749-74. PubMed ID: 9890058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weighing the risks and benefits of vaccination.
    Glickman LT
    Adv Vet Med; 1999; 41():701-13. PubMed ID: 9890055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulations for vaccines against emerging infections and agrobioterrorism in the United States of America.
    Elsken LA; Carr MY; Frana TS; Brake DA; Garland T; Smith K; Foley PL
    Rev Sci Tech; 2007 Aug; 26(2):429-41. PubMed ID: 17892163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing surveillance for dog and cat vaccines: new resources in changing times.
    Moore GE; Frana TS; Guptill LF; Ward MP; Lewis HB; Glickman LT
    J Am Vet Med Assoc; 2005 Oct; 227(7):1066-9. PubMed ID: 16220664
    [No Abstract]   [Full Text] [Related]  

  • 6. Veterinary Products Committee working group report on feline and canine vaccination.
    Gaskell RM; Gettinby G; Graham SJ; Skilton D
    Vet Rec; 2002 Feb; 150(5):126-34. PubMed ID: 11871665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination practices in veterinary medicine: standardization versus tailored to needs?
    Martinod S
    Adv Vet Med; 1999; 41():657-68. PubMed ID: 9890052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COVID-19 Vaccines: A Description of Adverse Events of Reactions Reported in Kansas.
    Mills K; Tri A; Nilsen K
    Kans J Med; 2022; 15():39-47. PubMed ID: 35371387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory considerations for emergency use of non-USDA licensed vaccines in the United States.
    Hill RE; Foley PL; Carr MY; Elsken LA; Gatewood DM; Ludemann LR; Wilbur LA
    Dev Biol (Basel); 2003; 114():31-52. PubMed ID: 14677675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracking vaccine lot lifecycles using reports to the vaccine adverse event reporting system (VAERS).
    Dayan GH; Iskander J; Glasser J; English-Bullard R; Fullerton KE; Chen R
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):671-6. PubMed ID: 15662715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system.
    Alguacil-Ramos AM; Muelas-Tirado J; Garrigues-Pelufo TM; Portero-Alonso A; Diez-Domingo J; Pastor-Villalba E; Lluch-Rodrigo JA
    Public Health; 2016 Jun; 135():66-74. PubMed ID: 26976484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M; Reich L; Chung S
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventable mix-ups of tuberculin and vaccines: reports to the US Vaccine and Drug Safety Reporting Systems.
    Chang S; Pool V; O'Connell K; Polder JA; Iskander J; Sweeney C; Ball R; Braun MM
    Drug Saf; 2008; 31(11):1027-33. PubMed ID: 18840022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration : A Cohort Study.
    Tau N; Yahav D; Shepshelovich D
    Ann Intern Med; 2020 Sep; 173(6):445-449. PubMed ID: 32716700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of implantable cardiac device reliability. The case for improved postmarketing risk assessment and surveillance.
    Laskey W; Awad K; Lum J; Skodacek K; Zimmerman B; Selzman K; Zuckerman B
    Am J Ther; 2012 Jul; 19(4):248-54. PubMed ID: 22668602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
    Varricchio F; Iskander J; Destefano F; Ball R; Pless R; Braun MM; Chen RT
    Pediatr Infect Dis J; 2004 Apr; 23(4):287-94. PubMed ID: 15071280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of efficacy of heartworm preventive products at the FDA.
    Hampshire VA
    Vet Parasitol; 2005 Oct; 133(2-3):191-5. PubMed ID: 16099105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.